Strategy

AKLRD identifies and validates active phytochemicals whose safety and efficacy in their original form have already been established in non-prescription markets

Synthetic versions of phytochemicals, whose safety and efficacy in their original form have already been established, are taken to proof of concept through robust clinical evaluation.

This strategy of using well-characterised active components considerably improves the chances of successfully completing preclinical toxicity studies, avoiding unexpected side effects and showing efficacy in formal clinical trials.

It is AKLRD’s intention to access global markets via partner(s) following proof of concept.